Equities

Ivision Tech SpA

Ivision Tech SpA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.96
  • Today's Change0.02 / 1.03%
  • Shares traded25.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 25 2024 16:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ivision Tech SpA, or iVision Tech, is an Italy-based Company engaged in the production of Glasses. The Company is active in the design and manufacture of acetate eyeglass frames and sunglasses, and combination eyewear (made of two parts in different materials: acetate frontals and metal temples). In addition, the Firm acts as a wholesaler in collaboration with international brands from the luxury sector. iVision Tech operates an integrated production cycle ranging from hand-drawing and/or 3D prototyping to the final stages of assembly and finishing. The Company operates through two divisions. iVision Eyewear segment is active in the design, prototype development, industrialization, and mass production stages of acetate eyewear using specialized machinery and software. iVision R&D business unit is a specific R&D division focused on technological innovations. Moreover, the Firm is engaged in other two activities: the sale of medial masks and of eyeglass machineries.

  • Revenue in EUR (TTM)9.37m
  • Net income in EUR53.62k
  • Incorporated--
  • Employees146.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IVN:MIL since
announced
Transaction
value
Maison Henry Jullien-Business UnitDeal completed22 Sep 202322 Sep 2023Deal completed30.67%--
Data delayed at least 15 minutes, as of Jun 25 2024 16:29 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Redsense Medical AB (publ)1.77m-672.85k9.64m5.00--4.95--5.46-0.5389-0.53891.411.420.72614.515.023,970,800.00-27.67-18.66-31.75-20.9950.1169.02-38.11-46.282.21--0.00--74.1128.9448.47---23.62--
Dignitana AB7.62m-1.64m10.89m28.00--39.56--1.43-0.2487-0.24871.150.03841.663.3514.613,175,519.00-35.81-42.21-97.80-68.9169.1166.09-21.55-57.290.3234-8.840.8571--17.9020.5922.52---15.31--
Spineguard SA4.31m-4.18m10.89m24.00--1.57--2.53-0.107-0.1070.11040.12550.38271.284.68179,700.00-37.12-23.69-52.43-42.7372.8975.60-97.00-45.021.73-13.510.3384---22.98-10.65-74.81--89.42--
Nanexa AB2.57m-6.28m10.96m19.00--1.32--4.26-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Medinice SA52.39k-1.20m11.20m16.00--1.54--213.69-0.8224-0.82240.03594.970.0059--0.369814,062.50-13.46-12.47-13.77-12.9627.1162.64-2,297.33-1,404.30----0.017---10.71189.32-4.41--177.91--
Laboratoires Euromedis SA34.04m13.11m11.99m54.000.90620.52590.90010.35224.604.6011.667.930.64153.053.92630,347.6024.718.7634.6512.450.533815.5738.526.101.46-26.380.3031---37.18--320.97------
Implanet SA7.45m-6.68m12.50m41.00------1.68-0.1704-0.17040.1933-0.00420.59310.90834.19182,973.00-53.17-37.44-159.90-86.7456.8359.59-89.65-67.430.2932-24.761.03---7.242.08-88.59---2.20--
Medicon Hellas SA19.86m2.06m12.55m98.006.110.73663.250.63190.46520.46524.493.860.6111.882.16--6.736.488.018.1572.1474.4411.0211.21--11.500.3853---3.4110.33-16.688.0824.76--
aap Implantate AG-100.00bn-100.00bn13.07m111.00--0.7511----------1.58-----------28.07---34.07--90.66---74.070.9396--0.1584---5.341.10-1.67---25.10--
Neola Medical AB0.00-804.11k13.35m7.00--1.96-----0.1536-0.15360.001.090.00----0.00-11.63-17.04-12.52-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Iconovo AB753.27k-3.77m13.45m29.00--1.12--17.85-3.68-3.680.7038.450.0554--1.24292,079.00-27.74-25.43-30.85-28.24234.21134.57-500.63-215.16----0.0666---58.65-9.884.71--34.70--
Ivision Tech SpA9.37m53.62k13.46m146.00250.972.068.211.440.00770.00771.350.9418------64,151.30--------57.67--0.5725--1.222.380.4058--18.59---81.01------
Theraclion SA1.87m-4.88m15.27m30.00--2.25--8.17-0.1362-0.13620.05040.14810.10210.2821.2366,785.00-26.65-40.08-35.36-59.9654.2152.19-260.94-276.132.50-56.170.2546---16.58-12.66-32.02--11.77--
BibbInstruments AB0.00-1.02m15.53m----5.62-----0.4401-0.44010.001.060.00-------36.33-39.57-39.77-42.71--59.36---8,032.402.03--0.00------2.72---1.94--
Episurf Medical AB978.23k-8.19m16.79m25.00--1.32--17.16-0.266-0.2660.03180.18610.0852--5.24392,857.20-71.42-47.46-81.48-52.01-----838.18-1,019.292.54--0.068--53.6219.78-22.64---0.4158--
Alpha Mos SA4.51m-4.74m17.31m53.00------3.84-0.4345-0.43450.4127-0.74280.5992.937.3685,000.00-63.06-47.80-521.78-139.0945.5568.00-105.28-68.640.2498-6.78-----22.464.97-76.91------
Data as of Jun 25 2024. Currency figures normalised to Ivision Tech SpA's reporting currency: Euro EUR

Institutional shareholders

1.25%Per cent of shares held by top holders
HolderShares% Held
Banor SIM SpAas of 31 Mar 202487.00k1.25%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.